MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Primary demo aims were being to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, even though one https://denisr998gsc2.wikitelevisions.com/user